drugset / Trial / NCT05079438
Dendrobium Huoshanense Suppository in Rectal Cancer
RandomizedParallel-groupSingle-blindPrevention
Summary
To evaluates the role of Dendrobium Huoshanense Suppository for radiation proctitis in locally advanced rectal cancer treated by capecitabine and irinotecan based neoadjuvant chemoradiation.
Timeline
- Start
- 2021-09-07
- Primary completion
- 2023-07-30
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendrobium Huoshanense Suppository | Unknown | 1.7 g | Rectal |
Indications
No indication recorded.